Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects (Q51553376)

7 April 2018

title

Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects (English)

1 reference

7 April 2018

1 reference

1 reference

Nobuhiro Tahara

1 reference

7 April 2018

Sho-Ichi Yamagishi

1 reference

7 April 2018

Takanori Matsui

1 reference

7 April 2018

Masayoshi Takeuchi

1 reference

7 April 2018

Yoshikazu Nitta

1 reference

7 April 2018

Norihiro Kodama

1 reference

7 April 2018

Minori Mizoguchi

1 reference

7 April 2018

Tsutomu Imaizumi

1 reference

7 April 2018

publication date

7 July 2010

1 reference

7 April 2018

Cardiovascular Therapeutics

published in

1 reference

7 April 2018

volume

1 reference

7 April 2018

issue

1 reference

7 April 2018

page(s)

42-48

1 reference

7 April 2018

Advanced protein glycosylation in diabetes and aging

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Atherosclerosis and diabetes: the RAGE connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Modulating an oxidative-inflammatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

TAGE (toxic AGEs) theory in diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Association between acute-phase reactants and advanced glycation end products in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Advanced glycation end products and endothelial dysfunction in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase C alpha-mediated mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Pigment epithelium-derived factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant alpha-lipoic acid on insulin resistance in the obese Zucker rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00177.X

10.1111/J.1755-5922.2010.00177.X

21 January 2018

Identifiers

DOI

1 reference

7 April 2018

1 reference

7 April 2018